Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients

被引：0
|
作者：
Rossana Tallerico
Costanza M Cristiani
Mariaelena Capone
Gabriele Madonna
Domenico Mallardo
Ester Simeone
Andrea Dominijanni
Antonio M Grimaldi
Francesco Colucci
Paolo A Ascierto
Ennio Carbone
机构：
[1] University "Magna Graecia" of Catanzaro,Tumorimmunology and Immunopathology Laboratory, Department of Experimental and Clinic Medicine
[2] Istituto Nazionale Tumori Fondazione "G. Pascale",Melanoma. CancerImmunotherapy and Innovative Therapy Unit
[3] Immunohaematological Transfusion Medicine Centre “Pugliese-Ciaccio” Hospital of Catanzaro,Department of Obstetrics and Gynaecology
[4] University of Cambridge Clinical School,Department of Microbiology Cell and Tumorbiology (MTC)
[5] Karolinska Institutet,undefined
来源：
Journal of Translational Medicine | / 13卷 / Suppl 1期
关键词：
Melanoma; Metastatic Melanoma; Melanoma Patient; Ipilimumab; Cell Immune Response;
D O I：
10.1186/1479-5876-13-S1-O8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Tirumani, Sree Harsha
    Ramaiya, Nikhil H.
    Keraliya, Abhishek
    Bailey, Nancy D.
    Ott, Patrick A.
    Hodi, F. Stephen
    Nishino, Mizuki
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1185 - 1192
  • [22] Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
    Drew Hotson
    Ryan Alvarado
    Andy Conroy
    Santosh Putta
    Ester Simeone
    Assunta Esposito
    Mariaelena Capone
    Gabriele Madonna
    Antonio M Grimaldi
    David B Rosen
    Spencer Liang
    Alessandra Cesano
    Carmela Cacciapuoti
    Paolo A Ascierto
    Rachael E Hawtin
    Journal of Translational Medicine, 12 (Suppl 1)
  • [23] GASTROINTESTINAL EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB AND NIVOLUMAB
    Irwin, D.
    Davis, B. M.
    Bell, J.
    Galaznik, A.
    Garcia-Ribas, I
    VALUE IN HEALTH, 2018, 21 : S14 - S14
  • [24] Prognostic score for patients with advanced melanoma treated with ipilimumab
    Diem, Stefan
    Kasenda, Benjamin
    Martin-Liberal, Juan
    Lee, Alexander
    Chauhan, Dharmisha
    Gore, Martin
    Larkin, James
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (18) : 2785 - 2791
  • [25] STUDY OF A COHORT OF PATIENTS WITH METASTATIC MELANOMA TREATED WITH IPILIMUMAB
    Roussel, A.
    Berthe, A.
    Quereux, G.
    Dreno, B. R. I.
    Thomare, P.
    ANNALS OF ONCOLOGY, 2013, 24 : 36 - 36
  • [26] Predictive value of circulating B cells and T cell subsets in melanoma patients treated with neoadjuvant ipilimumab and interferon.
    Khunger, Arjun
    Sarikonda, Ghanashyam
    Tsau, Jenn
    Alfonso, Zeni
    Gao, Jane
    Pahuja, Anil
    Laing, Christian
    Kim, Ju Young
    Bordeaux, Jennifer
    Vaupel, Christine
    Dakappagari, Naveen
    Tangri, Shabnam
    Tarhini, Ahmad A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Immune cell subsets as markers of response to ipilimumab in metastatic melanoma
    Reith, M.
    Wagner, N.
    Tarnanidis, K.
    Lichtenberger, R.
    Umansky, V.
    Utikal, J.
    Gebhardt, C.
    EXPERIMENTAL DERMATOLOGY, 2015, 24 (03) : E40 - E40
  • [28] Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
    Koller, Kristian M.
    Mackley, Heath B.
    Liu, Jason
    Wagner, Henry
    Talamo, Giampaolo
    Schell, Todd D.
    Pameijer, Colette
    Neves, Rogerio I.
    Anderson, Bryan
    Kokolus, Kathleen M.
    Mallon, Carol A.
    Drabick, Joseph J.
    CANCER BIOLOGY & THERAPY, 2017, 18 (01) : 36 - 42
  • [29] Roles for T and NK cells in the innate immune response to Shigella flexneri
    Le-Barillec, K
    Magalhaes, JG
    Corcuff, E
    Thuizat, A
    Sansonetti, PJ
    Phalipon, A
    Di Santo, JP
    JOURNAL OF IMMUNOLOGY, 2005, 175 (03): : 1735 - 1740
  • [30] Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002
    Daud, A.
    Puzanov, I.
    Dummer, R.
    Schadendorf, D.
    Hamid, O.
    Robert, C.
    Hodi, F. S.
    Schachter, J.
    Sosman, J.
    Pavlick, A. C.
    Gonzalez, R.
    Blank, C. U.
    Cranmer, L.
    O'Day, S. J.
    Salama, A. K.
    Margolin, K.
    Yang, J.
    Moreno, B. Homet
    Ibrahim, N.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2017, 28
12345